SCP
REGN icon

Seizert Capital Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Seizert Capital Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44.4M Sell
71,169
-14,512
-17% -$9.88M 1.83% 24
2026
Q1 		$66.2M Sell
85,681
-9,024
-10% -$6.91M 3.05% 1
2025
Q4 		$73.1M Sell
94,705
-4,085
-4% -$2.77M 3.09% 6
2025
Q3 		$55.5M Buy
98,790
+12,810
+15% +$7.24M 2.41% 15
2025
Q2 		$45.1M Buy
85,980
+3,308
+4% +$1.85M 1.98% 22
2025
Q1 		$52.4M Buy
82,672
+28,368
+52% +$19.5M 2.4% 11
2024
Q4 		$38.7M Buy
54,304
+8,529
+19% +$7.16M 1.75% 26
2024
Q3 		$48.1M Sell
45,775
-6,185
-12% -$6.88M 2.17% 12
2024
Q2 		$54.6M Sell
51,960
-4,354
-8% -$4.22M 2.71% 8
2024
Q1 		$54.2M Buy
56,314
+543
+1% +$516K 2.5% 10
2023
Q4 		$49M Sell
55,771
-3,024
-5% -$2.49M 2.48% 9
2023
Q3 		$48.4M Buy
58,795
+1,323
+2% +$1.04M 2.56% 10
2023
Q2 		$41.3M Sell
57,472
-966
-2% -$745K 2.21% 13
2023
Q1 		$48M Sell
58,438
-4,288
-7% -$3.23M 2.64% 9
2022
Q4 		$45.3M Sell
62,726
-8,752
-12% -$6.46M 2.4% 8
2022
Q3 		$49.2M Sell
71,478
-13,823
-16% -$8.7M 2.78% 4
2022
Q2 		$50.4M Buy
85,301
+3,696
+5% +$2.4M 2.67% 6
2022
Q1 		$57M Sell
81,605
-5,757
-7% -$3.64M 2.62% 4
2021
Q4 		$55.2M Sell
87,362
-1,737
-2% -$1.07M 2.47% 6
2021
Q3 		$53.9M Buy
89,099
+2,037
+2% +$1.26M 2.47% 8
2021
Q2 		$48.6M Buy
87,062
+2,485
+3% +$1.26M 2.32% 9
2021
Q1 		$40M Buy
84,577
+35,991
+74% +$17.5M 2.09% 13
2020
Q4 		$23.5M Buy
48,586
+12,852
+36% +$6.94M 1.37% 31
2020
Q3 		$20M Sell
35,734
-711
-2% -$431K 1.31% 34
2020
Q2 		$22.7M Sell
36,445
-4,033
-10% -$2.29M 1.54% 29
2020
Q1 		$19.8M Sell
40,478
-26,381
-39% -$10.9M 1.46% 30
2019
Q4 		$25.1M Sell
66,859
-9,228
-12% -$3.1M 1.25% 33
2019
Q3 		$21.1M Buy
+76,087
New +$22.5M 1.06% 37

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Seizert Capital Partners's REGN Position: Q2 2026 in Review

Seizert Capital Partners reduced its Regeneron Pharmaceuticals (REGN) stake by 17% in Q2 2026, selling an estimated $9.88M and leaving 71,169 shares worth $44.4M. The position accounts for 1.83% of the portfolio, ranked #24.

Seizert Capital Partners first reported a position in REGN in Q3 2019 and has held it in 28 quarters since. The position peaked at $73.1M in Q4 2025. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Seizert Capital Partners held 71,169 shares of Regeneron Pharmaceuticals worth $44.4M as of Q2 2026.
  • Seizert Capital Partners sold 14,512 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $9.88M.
  • Regeneron Pharmaceuticals made up 1.83% of Seizert Capital Partners's portfolio in Q2 2026, its #24 holding.
  • Seizert Capital Partners first reported a position in Regeneron Pharmaceuticals in Q3 2019 and has held it in 28 quarters since.
  • Seizert Capital Partners's Regeneron Pharmaceuticals position peaked at $73.1M in Q4 2025.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Seizert Capital Partners's 13F filing for Q2 2026, filed 5 Aug 2026.